Bain Capital Life Sciences Investors, LLC

Q3 2019 13F Holdings Report, Stock Holdings

Signature - Title
Adam Koppel - Partner of Bain Capital Life Sciences Investors, LLC
Location
Boston, MA
Holdings as of
September 30, 2019
Value $
$388M
Num holdings
7
Date filed
11/14/2019, 08:32 AM
Description
All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q2 2019 - Aug 14, 2019
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2019 Q3 compared to 2019 Q2 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Adam Koppel Managing Dir. of Bain Capital Life Sciences Investors, LLC Boston, Massachusetts 11/14/2019

Bain Capital Life Sciences Investors, LLC is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on August 22, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of September 30, 2019, such persons held 7,525,000 shares of DVAX common stock.

Other Included Managers (2):

Num Name Location File Number
1 Bain Capital Life Sciences Partners, LP Boston, MA 028-18476
2 Bain Capital Life Sciences Fund, L.P. Boston, MA 028-18478